PEPTIC Trial: Stress Ulcer Prophylaxis With PPIs vs H2RBs and Mortality in the ICU 

An estimated 2.5% of adults acutely admitted to ICUs develop upper GI bleeding and 70% are prescribed stress ulcer prophylaxis. A 2020 cluster randomized trial found no difference in in-hospital mortality among nearly 27,000 mechanically patients assigned to an intensive/critical care unit (ICU/CCU)-level strategy of stress ulcer prophylaxis with proton pump inhibitors (PPIs) vs histamine-2 receptor blockers (H2RBs).
In this video, Paul J. Young, PhD, of Wellington Hospital in New Zealand, presented findings from the PEPTIC Trial at the Critical Care Reviews 2020 meeting (#CCR20), on January 17 in Belfast, Northern Ireland. An oral editorial and Q&A session follows.
Click ja.ma/2RwwkeA for full trial details.
Video used with permission.